CoChat
Sign Up
Cited by 116

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Cystatin C in Alzheimer's disease

Kaur, Gurjinder, Levy, Efrat·2012·Frontiers in Molecular Neuroscience
DOI 10.3389/fnmol.2012.00079PMC PMC3390601
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnmol.2012.00079

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 141

  1. Abrahamson M. Buttle D. J. Mason R. W. Hansson H. Grubb A. O. Lilja H. Ohlsson K. (1991). Regulation of cystatin C activity by serine proteinases. Biomed. Biochim. Acta 50, 587– 593 1801727
  2. Abrahamson M. Islam M. Q. Szpirer J. Szpirer C. Levan G. (1989). The human cystatinSgene, SSC (CST3), mutated in hereditary cystatin C amyloid angiopathy, is located on chromosome 20. Hum. Genet. 82, 223– 226 2567273
  3. Abrahamson M. Olafsson I. Palsdottir A. Ulvsback M. Lundwall A. Jensson O. Grubb A. O. (1990). Structure and expression of the human cystatin C gene. Biochem. J. 268, 287– 294 2363674 PMC1131430
  4. Aronica E. van Vliet E. A. Hendriksen E. Troost D. Lopes da Silva F. H. Gorter J. A. (2001). Cystatin C, a cysteine protease inhibitor, is persistently up-regulated in neurons and glia in a rat model for mesial temporal lobe epilepsy. Eur. J. Neurosci. 14, 1485– 1491 10.1046/j.0953-816x.2001.01779.x 11722610 · DOI
  5. Babiloni C. Benussi L. Binetti G. Bosco P. Busonero G. Cesaretti S. Dal Forno G. Del Percio C. Ferri R. Frisoni G. Roberta G. Rodriguez G. Squitti R. Rossini P. M. (2006). Genotype (cystatin C) and EEG phenotype in Alzheimer disease and mild cognitive impairment: a multicentric study. Neuroimage 29, 948– 964 10.1016/j.neuroimage.2005.08.030 16213753 · DOI
  6. Bai Y. Markham K. Chen F. Weerasekera R. Watts J. Horne P. Wakutani Y. Bagshaw R. Mathews P. M. Fraser P. E. Westaway D. St. George-Hyslop P. Schmitt-Ulms G. (2008). The in vivo brain interactome of the amyloid precursor protein. Mol. Cell Proteomics 7, 15– 34 10.1074/mcp.M700077-MCP200 17934213 · DOI
  7. Balbin M. Abrahamson M. (1991). SstII polymorphic sites in the promoter region of the human cystatin C gene. Hum. Genet. 87, 751– 752 1682236
  8. Balbin M. Grubb A. O. Abrahamson M. (1993). An Ala/Thr variation in the coding region of the human cystatinSgene, SSC (CST3) detected as a SstII polymorphism. Hum. Genet. 92, 206– 207 8103758
  9. Benussi L. Ghidoni R. Steinhoff T. Alberici A. Villa A. Mazzoli F. Nicosia F. Barbiero L. Broglio L. Feudatari E. Signorini S. Finckh U. Nitsch R. M. Binetti G. (2003). Alzheimer disease-associated cystatin C variant undergoes impaired secretion. Neurobiol. Dis. 13, 15– 21 10.1016/S0969-9961(03)00012-3 12758063 · DOI
  10. Bernstein H. G. Kirschke H. Wiederanders B. Pollak K. H. Zipress A. Rinne A. (1996). The possible place of cathepsins and cystatins in the puzzle of Alzheimer disease: a review. Mol. Chem. Neuropathol. 27, 225– 247 9147410
  11. Bernstein H. G. Rinne R. Kirschke H. Jarvinen M. Knofel B. Rinne A. (1994). Cystatin A-like immunoreactivity is widely distributed in human brain and accumulates in neuritic plaques of Alzheimer disease subjects. Brain Res. Bull. 33, 477– 481 8186992
  12. Beyer K. Lao J. I. Gomez M. Riutort N. Latorre P. Mate J. L. Ariza A. (2001). Alzheimer's disease and the cystatin C gene polymorphism: an association study. Neurosci. Lett. 315, 17– 20 10.1016/S0304-3940(01)02307-2 11711204 · DOI
  13. Bobek L. A. Levine M. J. (1992). Cystatins-inhibitors of cysteine proteinases. Crit. Rev. Oral Biol. Med. 3, 307– 332 10.1177/10454411920030040101 1391414 · DOI
  14. Butterfield D. A. Boyd-Kimball D. (2004). Amyloid β-peptide(1–42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain. Brain Pathol. 14, 426– 432 15605990 PMC8096022
  15. Buxbaum J. N. Ye Z. Reixach N. Friske L. Levy C. Das P. Golde T. Masliah E. Roberts A. R. Bartfai T. (2008). Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Aβ toxicity. Proc. Natl. Acad. Sci. U.S.A. 105, 2681– 2686 10.1073/pnas.0712197105 18272491 PMC2268196 · DOI
  16. Cataldo A. M. Nixon R. A. (1990). Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc. Natl. Acad. Sci. U.S.A. 87, 3861– 3865 1692625 PMC54003
  17. Cathcart H. M. Huang R. Lanham I. S. Corder E. H. Poduslo S. E. (2005). Cystatin C as a risk factor for Alzheimer disease. Neurology 64, 755– 757 10.1212/01.WNL.0000151980.42337.44 15728313 · DOI
  18. Chauhan V. P. Ray I. Chauhan A. Wisniewski H. M. (1999). Binding of gelsolin, a secretory protein, to amyloid β-protein. Biochem. Biophys. Res. Commun. 258, 241– 246 10.1006/bbrc.1999.0623 10329371 · DOI
  19. Choi S. H. Leight S. N. Lee V. M. Li T. Wong P. C. Johnson J. A. Saraiva M. J. Sisodia S. S. (2007). Accelerated Aβ deposition in APPswe/PS1deltaE9 mice with hemizygous deletions of TTR (transthyretin). J. Neurosci. 27, 7006– 7010 10.1523/JNEUROSCI.1919-07.2007 17596449 PMC6672232 · DOI
  20. Cohen D. H. Feiner H. Jensson O. Frangione B. (1983). Amyloid fibril in hereditary cerebral hemorrhage with amyloidosis (HCHWA) is related to the gastroentero-pancreatic neuroendocrine protein, γ trace. J. Exp. Med. 158, 623– 628 6886625 PMC2187337
  21. Craig-Schapiro R. Kuhn M. Xiong C. Pickering E. H. Liu J. Misko T. P. Perrin R. J. Bales K. R. Soares H. Fagan A. M. Holtzman D. M. (2011). Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS ONE 6: e18850 10.1371/journal.pone.0018850 21526197 PMC3079734 · DOI
  22. Crawford F. C. Freeman M. J. Schinka J. A. Abdullah L. I. Gold M. Hartman R. Krivian K. Morris M. D. Richards D. Duara R. Anand R. Mullan M. J. (2000). A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology 55, 763– 768 10993992
  23. Deng A. Irizarry M. C. Nitsch R. M. Growdon J. H. Rebeck G. W. (2001). Elevation of cystatin C in susceptible neurons in Alzheimer's disease. Am. J. Pathol. 159, 1061– 1068 10.1016/S0002-9440(10)61781-6 11549598 PMC1850464 · DOI
  24. Dodel R. C. Du Y. Depboylu C. Kurz A. Eastwood B. Farlow M. Oertel W. H. Muller U. Riemenschneider M. (2002). A polymorphism in the cystatin C promoter region is not associated with an increased risk of AD. Neurology 58, 664 11865157
  25. Filler G. Bokenkamp A. Hofmann W. Le Bricon T. Martinez-Bru C. Grubb A. (2005). Cystatin C as a marker of GFR–history, indications, and future research. Clin. Biochem. 38, 1– 8 10.1016/j.clinbiochem.2004.09.025 15607309 · DOI
  26. Finckh U. von der Kammer H. Velden J. Michel T. Andresen B. Deng A. Zhang J. Muller-Thomsen T. Zuchowski K. Menzer G. Mann U. Papassotiropoulos A. Heun R. Zurdel J. Holst F. Benussi L. Stoppe G. Reiss J. Miserez A. R. Staehelin H. B. Rebeck G. W. Hyman B. T. Binetti G. Hock C. Growdon J. H. Nitsch R. M. (2000). Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. Arch. Neurol. 57, 1579– 1583 10.1001/archneur.57.11.1579 11074789 · DOI
  27. Gauthier S. Kaur G. Mi W. Tizon B. Levy E. (2011). Protective mechanisms by cystatin C in neurodegenerative diseases. Front. Biosci. (Schol Ed.) 3, 541– 554 21196395 PMC3038625
  28. Ghidoni R. Benussi L. Glionna M. Desenzani S. Albertini V. Levy E. Emanuele E. Binetti G. (2010). Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment. J. Alzheimers Dis. 22, 985– 991 10.3233/JAD-2010-101095 20858959 · DOI
  29. Ghidoni R. Benussi L. Paterlini A. Missale C. Usardi A. Rossi R. Barbiero L. Spano P. Binetti G. (2007). Presenilin mutations alter cystatin C trafficking in mouse primary neurons. Neurobiol. Aging 28, 371– 376 10.1016/j.neurobiolaging.2006.01.007 16545890 · DOI
  30. Ghidoni R. Paterlini A. Albertini V. Glionna M. Monti E. Schiaffonati L. Benussi L. Levy E. Binetti G. (2011). Cystatin C is released in association with exosomes: a new tool of neuronal communication which is unbalanced in Alzheimer's disease. Neurobiol. Aging 32, 1435– 1442 10.1016/j.neurobiolaging.2009.08.013 19773092 PMC2891183 · DOI
  31. Ghiso J. Plant G. T. Revesz T. Wisniewski T. Frangione B. (1995). Familial cerebral amyloid angiopathy (British type) with nonneuritic amyloid plaque formation may be due to a novel amyloid protein. J. Neurol. Sci. 129, 74– 75 10.1016/0022-510X(94)00274-R 7751849 · DOI
  32. Ghiso J. Pons-Estel B. Frangione B. (1986). Hereditary cerebral amyloid angiopathy: the amyloid fibrils contain a protein which is a variant of cystatin C, an inhibitor of lysosomal cysteine proteases. Biochem. Biophys. Res. Commun. 136, 548– 554 10.1016/0006-291X(86)90475-4 3707586 · DOI
  33. Goddard K. A. Olson J. M. Payami H. van der Voet M. Kuivaniemi H. Tromp G. (2004). Evidence of linkage and association on chromosome 20 for late-onset Alzheimer disease. Neurogenetics 5, 121– 128 10.1007/s10048-004-0174-3 15034766 · DOI
  34. Graffagnino C. Herbstreith M. H. Schmechel D. E. Levy E. Roses A. D. Alberts M. J. (1995). Cystatin C mutation in an elderly man with sporadic amyloid angiopathy and intracerebral hemorrhage. Stroke 26, 2190– 2193 10.1161/01.STR.26.11.2190 7482672 · DOI
  35. Grubb A. O. (1992). Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin. Nephrol. 38 Suppl. 1, S20– S27 1284235
  36. Gudmundsson G. Hallgrimsson J. Jonasson T. A. Bjarnason O. (1972). Hereditary cerebral haemorrhage with amyloidosis. Brain 95, 387– 404 10.1093/brain/95.2.387 4655034 · DOI
  37. Haan J. Maat-Schieman M. L. C. van Duinen S. G. Jensson O. Thorsteinsson L. Roos R. A. C. (1994). Co-localization of β/A4 and cystatin C in cortical blood vessels in Dutch, but not in Icelandic hereditary cerebral hemorrhage with amyloidosis. Acta Neurol. Scand. 89, 367– 371 8085435
  38. Hakansson K. Huh C. Grubb A. Karlsson S. Abrahamson M. (1996). Mouse and rat cystatin C: Escherichia coli production, characterization and tissue distribution. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 114, 303– 311 8761177
  39. Hansson S. F. Andreasson U. Wall M. Skoog I. Andreasen N. Wallin A. Zetterberg H. Blennow K. (2009). Reduced levels of amyloid-β-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J. Alzheimers Dis. 16, 389– 397 10.3233/JAD-2009-0966 19221428 · DOI
  40. Hasegawa A. Naruse M. Hitoshi S. Iwasaki Y. Takebayashi H. Ikenaka K. (2007). Regulation of glial development by cystatin C. J. Neurochem. 100, 12– 22 10.1111/j.1471-4159.2006.04169.x 17064358 · DOI
  41. Helisalmi S. Vakeva A. Hiltunen M. Soininen H. (2009). Flanking markers of cystatin c (CST3) gene do not show association with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 27, 318– 321 10.1159/000209278 19293566 · DOI
  42. Hendriksen H. Datson N. A. Ghijsen W. E. van Vliet E. A. da Silva F. H. Gorter J. A. Vreugdenhil E. (2001). Altered hippocampal gene expression prior to the onset of spontaneous seizures in the rat post-status epilepticus model. Eur. J. Neurosci. 14, 1475– 1484 10.1046/j.0953-816x.2001.01778.x 11722609 · DOI
  43. Hill I. E. Preston E. Monette R. MacManus J. P. (1997). A comparison of cathepsin B processing and distribution during neuronal death in rats following global ischemia or decapitation necrosis. Brain Res. 751, 206– 216 10.1016/S0006-8993(96)01403-5 9099807 · DOI
  44. Hochwald G. M. Pepe A. J. Thorbecke G. J. (1967). Trace proteins in biological fluids. IV. Physicochemical properties and sites of formation of γ trace and β trace proteins. Proc. Soc. Exp. Biol. Med. 124, 961– 966 4164643
  45. Hua Y. Zhao H. Lu X. Kong Y. Jin H. (2012). Meta-analysis of the cystatin C(CST3) Gene G73A polymorphism and susceptibility to Alzheimer's disease. Int. J. Neurosci. [Epub ahead of print]. 10.3109/00207454.2012.672502 22435454 · DOI
  46. Huh C. G. Hakansson K. Nathanson C. M. Thorgeirsson U. P. Jonsson N. Grubb A. Abrahamson M. Karlsson S. (1999). Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene. Mol. Pathol. 52, 332– 340 10748866 PMC395718
  47. Ii K. Ito H. Kominami E. Hirano A. (1993). Abnormal distribution of cathepsin proteinases and endogenous inhibitors (cystatins) in the hippocampus of patients with Alzheimer's disease, parkinsonism-dementia complex on Guam, and senile dementia and in the aged. Virchows Arch. A Pathol. Anat. Histopathol. 423, 185– 194 8236812
  48. Ishimaru H. Ishikawa K. Ohe Y. Takahashi A. Maruyama Y. (1996). Cystatin C and apolipoprotein E immunoreactivities in CA1 neurons in ischemic gerbil hippocampus. Brain Res. 709, 155– 162 10.1016/0006-8993(95)01232-X 8833751 · DOI
  49. Itoh Y. Yamada M. Hayakawa M. Otomo E. Miyatake T. (1993). Cerebral amyloid angiopathy: a significant cause of cerebellar as well as lobar cerebral hemorrhage in the elderly. J. Neurol. Sci. 116, 135– 141 8336159
  50. Jelic V. Julin P. Shigeta M. Nordberg A. Lannfelt L. Winblad B. Wahlund L. O. (1997). Apolipoprotein E epsilon4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence. J. Neurol. Neurosurg. Psychiatr. 63, 59– 65 10.1136/jnnp.63.1.59 9221969 PMC2169641 · DOI
  51. Juszczyk P. Paraschiv G. Szymanska A. Kolodziejczyk A. S. Rodziewicz-Motowidlo S. Grzonka Z. Przybylski M. (2009). Binding epitopes and interaction structure of the neuroprotective protease inhibitor cystatin C with β-amyloid revealed by proteolytic excision mass spectrometry and molecular docking simulation. J. Med. Chem. 52, 2420– 2428 10.1021/jm801115e 19317448 · DOI
  52. Kaeser S. A. Herzig M. C. Coomaraswamy J. Kilger E. Selenica M. L. Winkler D. T. Staufenbiel M. Levy E. Grubb A. Jucker M. (2007). Cystatin C modulates cerebral β-amyloidosis. Nat. Genet. 39, 1437– 1439 10.1038/ng.2007.23 18026102 · DOI · Paper page
  53. Katakai K. Shinoda M. Kabeya K. Watanabe M. Ohe Y. Mori M. Ishikawa K. (1997). Changes in distribution of cystatin C, apolipoprotein E and ferritin in rat hypothalamus after hypophysectomy. J. Neuroendocrinol. 9, 247– 253 9147287
  54. Kaur G. Mohan P. Pawlik M. Derosa S. Fajiculay J. Che S. Grubbs A. Ginsberg S. Nixon R. Levy E. (2010). Cystatin C rescues degenerating neurons in a cystatin B-knockout mouse model of progressive myoclonus epilepsy. Am. J. Pathol. 177, 2256– 2267 10.2353/ajpath.2010.100461 20889561 PMC2966785 · DOI
  55. Kiuru S. Salonen O. Haltia M. (1999). Gelsolin-related spinal and cerebral amyloid angiopathy. Ann. Neurol. 45, 305– 311 10072044
  56. Kiuru-Enari S. Somer H. Seppalainen A. M. Notkola I. L. Haltia M. (2002). Neuromuscular pathology in hereditary gelsolin amyloidosis. J. Neuropathol. Exp. Neurol. 61, 565– 571 12071640
  57. Klein W. L. Krafft G. A. Finch C. E. (2001). Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24, 219– 224 10.1016/S0166-2236(00)01749-5 11250006 · DOI · Paper page
  58. Kumada T. Hasegawa A. Iwasaki Y. Baba H. Ikenaka K. (2004). Isolation of cystatin C via functional cloning of astrocyte differentiation factors. Dev. Neurosci. 26, 68– 76 10.1159/000080714 15509901 · DOI
  59. Lehtovirta M. Partanen J. Kononen M. Hiltunen J. Helisalmi S. Hartikainen P. Riekkinen P. Sr. Soininen H. (2000). A longitudinal quantitative EEG study of Alzheimer's disease: relation to apolipoprotein E polymorphism. Dement. Geriatr. Cogn. Disord. 11, 29– 35 10629359
  60. Lehtovirta M. Partanen J. Kononen M. Soininen H. Helisalmi S. Mannermaa A. Ryynanen M. Hartikainen P. Riekkinen P. Sr. (1996). Spectral analysis of EEG in Alzheimer's disease: relation to apolipoprotein E polymorphism. Neurobiol. Aging 17, 523– 526 8832625
  61. Lenarcic B. Krasovec M. Ritonja A. Olafsson I. Turk V. (1991). Inactivation of human cystatin C and kininogen by human cathepsin D. FEBS Lett. 280, 211– 215 10.1016/0014-5793(91)80295-E 2013314 · DOI
  62. Lerner U. H. Grubb A. (1992). Human cystatin C, a cysteine proteinase inhibitor, inhibits bone resorption in vitro stimulated by parathyroid hormone and parathyroid hormone-related peptide of malignancy. J. Bone Miner. Res. 7, 433– 440 10.1002/jbmr.5650070411 1319105 · DOI
  63. Levy E. Lopez-Otin C. Ghiso J. Geltner D. Frangione B. (1989). Stroke in Icelandic patients with hereditary amyloid angiopathy is related to a mutation in the cystatinSgene, SSC, an inhibitor of cysteine proteases. J. Exp. Med. 169, 1771– 1778 2541223 PMC2189307
  64. Levy E. Sastre M. Kumar A. Gallo G. Piccardo P. Ghetti B. Tagliavini F. (2001). Codeposition of cystatin C with amyloid-ß protein in the brain of Alzheimer's disease patients. J. Neuropathol. Exp. Neurol. 60, 94– 104 11202179
  65. Lin C. Wang S. T. Wu C. W. Chuo L. J. Kuo Y. M. (2003). The association of a cystatin C gene polymorphism with late-onset alzheimer's disease and vascular dementia. Chin. J. Physiol. 46, 111– 115 14672279
  66. Lindahl P. Ripoll D. Abrahamson M. Mort J. S. Storer A. C. (1994). Evidence for the interaction of valine-in cystatin C with the S2 subsite of cathepsin B. Biochemistry 33, 4384– 4392 8155656
  67. Lukasiuk K. Pirttila T. J. Pitkanen A. (2002). Upregulation of cystatin C expression in the rat hippocampus during epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. Epilepsia 43(Suppl. 5), 137– 145 10.1046/j.1528-1157.43.s.5.20.x 12121309 · DOI
  68. Maetzler W. Schmid B. Synofzik M. Schulte C. Riester K. Huber H. Brockmann K. Gasser T. Berg D. Melms A. (2010). The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease. J. Alzheimers Dis. 19, 937– 942 10.3233/JAD-2010-1289 20157249 · DOI
  69. Mares J. Kanovsky P. Herzig R. Stejskal D. Vavrouskova J. Hlustik P. Vranova H. Burval S. Zapletalova J. Pidrman V. Obereigneru R. Suchy A. Vesely J. Podivinsky J. Urbanek K. (2009). New laboratory markers in diagnosis of Alzheimer dementia. Neurol. Res. 31, 1056– 1059 10.1179/174313209X385536 19589198 · DOI
  70. Maruyama H. Izumi Y. Oda M. Torii T. Morino H. Toji H. Sasaki K. Terasawa H. Nakamura S. Kawakami H. (2001). Lack of an association between cystatin C gene polymorphisms in Japanese patients with Alzheimer's disease. Neurology 57, 337– 339 11468325
  71. Maruyama K. Ikeda S. Ishihara T. Allsop D. Yanagisawa N. (1990). Immunohistochemical characterization of cerebrovascular amyloid in autopsied cases using antibodies to β protein and cystatin C. Stroke 21, 397– 403 10.1161/01.STR.21.3.397 2408196 · DOI
  72. Maruyama K. Kametani F. Ikeda S. Ishihara T. Yanagisawa N. (1992). Characterization of amyloid fibril protein from a case of CAA showing immunohistochemical reactivity for both β protein and cystatin C. Neurosci. Lett. 144, 38– 42 1436711
  73. Matsuoka Y. Saito M. LaFrancois J. Gaynor K. Olm V. Wang L. Casey E. Lu Y. Shiratori C. Lemere C. Duff K. (2003). Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J. Neurosci. 23, 29– 33 12514198 PMC6742136
  74. McCarron M. O. Nicoll J. A. Stewart J. Ironside J. W. Mann D. M. Love S. Graham D. I. Grubb A. (2000). Absence of cystatin C mutation in sporadic cerebral amyloid angiopathy-related hemorrhage. Neurology 54, 242– 244 10636160
  75. Mi W. Jung S. S. Yu H. Schmidt S. D. Nixon R. A. Mathews P. M. Tagliavini F. Levy E. (2009). Complexes of amyloid-β and cystatin C in the human central nervous system. J. Alzheimers Dis. 18, 273– 280 10.3233/JAD-2009-1147 19584436 PMC2792995 · DOI
  76. Mi W. Pawlik M. Sastre M. Jung S. S. Radvinsky D. S. Klein A. M. Sommer J. Schmidt S. D. Nixon R. A. Mathews P. M. Levy E. (2007). Cystatin C inhibits amyloid-β deposition in Alzheimer's disease mouse models. Nat. Genet. 39, 1440– 1442 10.1038/ng.2007.29 18026100 · DOI
  77. Miyake T. Gahara Y. Nakayama M. Yamada H. Uwabe K. Kitamura T. (1996). Up-regulation of cystatin C by microglia in the rat facial nucleus following axotomy. Brain Res. Mol. Brain Res. 37, 273– 282 8738161
  78. Mori F. Tanji K. Miki Y. Wakabayashi K. (2009). Decreased cystatin C immunoreactivity in spinal motor neurons and astrocytes in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 68, 1200– 1206 10.1097/NEN.0b013e3181bdcdce 19816197 · DOI
  79. Nagai A. Kobayashi S. Shimode K. Imaoka K. Umegae N. Fujihara S. Nakamura M. (1998). No mutations in cystatin C gene in cerebral amyloid angiopathy with cystatin C deposition. Mol. Chem. Neuropathol. 33, 63– 78 9493177
  80. Nairismagi J. Grohn O. H. Kettunen M. I. Nissinen J. Kauppinen R. A. Pitkanen A. (2004). Progression of brain damage after status epilepticus and its association with epileptogenesis: a quantitative MRI study in a rat model of temporal lobe epilepsy. Epilepsia 45, 1024– 1034 10.1111/j.0013-9580.2004.08904.x 15329065 · DOI
  81. Nakamura Y. Takeda M. Suzuki H. Hattori H. Tada K. Hariguchi S. Hashimoto S. Nishimura T. (1991). Abnormal distribution of cathepsins in the brain of patients with Alzheimer's disease. Neurosci. Lett. 130, 195– 198 10.1016/0304-3940(91)90395-A 1795881 · DOI
  82. Ndjole A. M. Bodolea C. Nilsen T. Gordh T. Flodin M. Larsson A. (2010). Determination of cerebrospinal fluid cystatin C on Architect ci(8200). J. Immunol. Methods 360, 84– 88 10.1016/j.jim.2010.06.012 20598708 · DOI
  83. Nitatori T. Sato N. Waguri S. Karasawa Y. Araki H. Shibanai K. Kominami E. Uchiyama Y. (1995). Delayed neuronal death in the CA1 pyramidal cell layer of the gerbil hippocampus following transient ischemia is apoptosis. J. Neurosci. 15, 1001– 1011 7869078 PMC6577848
  84. Noto D. Cefalu A. B. Barbagallo C. M. Pace A. Rizzo M. Marino G. Caldarella R. Castello A. Pernice V. Notarbartolo A. Averna M. R. (2005). Cystatin C levels are decreased in acute myocardial infarction: effect of cystatin C G73A gene polymorphism on plasma levels. Int. J. Cardiol. 101, 213– 217 10.1016/j.ijcard.2004.03.018 15882666 · DOI
  85. Okamoto K. Mizuno Y. Fujita Y. (2008). Bunina bodies in amyotrophic lateral sclerosis. Neuropathology 28, 109– 115 10.1111/j.1440-1789.2007.00873.x 18069968 · DOI
  86. Olafsson I. Thorsteinsson L. Jensson O. (1996). The molecular pathology of hereditary cystatin C amyloid angiopathy causing brain hemorrhage. Brain Pathol. 6, 121– 126 8737928
  87. Olson J. M. Goddard K. A. Dudek D. M. (2002). A second locus for very-late-onset Alzheimer disease: a genome scan reveals linkage to 20p and epistasis between 20p and the amyloid precursor protein region. Am. J. Hum. Genet. 71, 154– 161 10.1086/341034 12016588 PMC384972 · DOI
  88. Palm D. E. Knuckey N. W. Primiano M. J. Spangenberger A. G. Johanson C. E. (1995). Cystatin C, a protease inhibitor, in degenerating rat hippocampal neurons following transient forebrain ischemia. Brain Res. 691, 1– 8 10.1016/0006-8993(95)00520-Z 8590041 · DOI
  89. Palsdottir A. Abrahamson M. Thorsteinsson L. Arnason A. Olafsson I. Grubb A. O. Jensson O. (1988). Mutation in cystatin C gene causes hereditary brain haemorrhage. Lancet 2, 603– 604 10.1016/S0140-6736(88)90641-1 2900981 · DOI · Paper page
  90. Paraoan L. Ratnayaka A. Spiller D. G. Hiscott P. White M. R. Grierson I. (2004). Unexpected intracellular localization of the AMD-associated cystatin C variant. Traffic 5, 884– 895 10.1111/j.1600-0854.2004.00230.x 15479453 · DOI
  91. Paraoan L. White M. R. Spiller D. G. Grierson I. Maden B. E. (2001). Precursor cystatin C in cultured retinal pigment epithelium cells: evidence for processing through the secretory pathway. Mol. Membr. Biol. 18, 229– 236 11681790
  92. Parent J. M. Yu T. W. Leibowitz R. T. Geschwind D. H. Sloviter R. S. Lowenstein D. H. (1997). Dentate granule cell neurogenesis is increased by seizures and contributes to aberrant network reorganization in the adult rat hippocampus. J. Neurosci. 17, 3727– 3738 9133393 PMC6573703
  93. Parfitt M. Crook R. Roques P. Rossor M. Chartier-Harlin M. C. (1993). The cystatin-C gene is not linked to early onset familial Alzheimer's disease. Neurosci. Lett. 154, 81– 83 8361651
  94. Pasinetti G. M. Ungar L. H. Lange D. J. Yemul S. Deng H. Yuan X. Brown R. H. Cudkowicz M. E. Newhall K. Peskind E. Marcus S. Ho L. (2006). Identification of potential CSF biomarkers in ALS. Neurology 66, 1218– 1222 10.1212/01.wnl.0000203129.82104.07 16481598 · DOI
  95. Pawlik M. Sastre M. Calero M. Mathews P. M. Schmidt S. D. Nixon R. A. Levy E. (2004). Overexpression of human cystatin C in transgenic mice does not affect levels of endogenous brain amyloid β peptide. J. Mol. Neurosci. 22, 13– 18 10.1385/JMN:22:1-2:13 14742906 · DOI
  96. Pennacchio L. A. Bouley D. M. Higgins K. M. Scott M. P. Noebels J. L. Myers R. M. (1998). Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nat. Genet. 20, 251– 258 10.1038/3059 9806543 · DOI
  97. Perrin R. J. Craig-Schapiro R. Malone J. P. Shah A. R. Gilmore P. Davis A. E. Roe C. M. Peskind E. R. Li G. Galasko D. R. Clark C. M. Quinn J. F. Kaye J. A. Morris J. C. Holtzman D. M. Townsend R. R. Fagan A. M. (2011). Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS ONE 6: e16032 10.1371/journal.pone.0016032 21264269 PMC3020224 · DOI
  98. Pirttila T. J. Lukasiuk K. Hakansson K. Grubb A. Abrahamson M. Pitkanen A. (2005). Cystatin C modulates neurodegeneration and neurogenesis following status epilepticus in mouse. Neurobiol. Dis. 20, 241– 253 10.1016/j.nbd.2005.03.006 16242633 · DOI
  99. Pirttila T. J. Pitkanen A. (2006). Cystatin C expression is increased in the hippocampus following photothrombotic stroke in rat. Neurosci. Lett. 395, 108– 113 10.1016/j.neulet.2005.10.091 16309830 · DOI
  100. Price D. L. Martin L. J. Sisodia S. S. Walker L. C. Voytko M. L. Wagster M. V. Cork L. C. Koliatsos V. E. (1994). The aged nonhuman primate. A model for the behavioral and brain abnormalities occurring in aged humans, in Alzheimer's Disease, eds Terry R. D. Katzman R. Blick K. L. (New York, NY: Raven Press), 231– 245
  101. Roks G. Cruts M. Slooter A. J. Dermaut B. Hofman A. van Broeckhoven C. van Duijn C. M. (2001). The cystatin C polymorphism is not associated with early onset Alzheimer's disease. Neurology 57, 366– 367 11468337
  102. Saitoh E. Sabatini L. M. Eddy R. L. Shows T. B. Azen E. A. Isemura S. Sanada K. (1989). The human cystatinSgene, SSC (CST3) is a member of the cystatin gene family which is localized on chromosome 20. Biochem. Biophys. Res. Commun. 162, 1324– 1331 10.1016/0006-291X(89)90818-8 2764935 · DOI
  103. Sastre M. Calero M. Pawlik M. Mathews P. M. Kumar A. Danilov V. Schmidt S. D. Nixon R. A. Frangione B. Levy E. (2004). Binding of cystatin C to Alzheimer's amyloid b inhibits amyloid fibril formation. Neurobiol. Aging 25, 1033– 1043 10.1016/j.neurobiolaging.2003.11.006 15212828 · DOI
  104. Schwarzman A. L. Gregori L. Vitek M. P. Lyubski S. Strittmatter W. J. Enghilde J. J. Bhasin R. Silverman J. Weisgraber K. H. Coyle P. K. Zagorski M. G. Talafous J. Eisenberg M. Saunders A. M. Roses A. D. Goldgaber D. (1994). Transthyretin sequesters amyloid β protein and prevents amyloid formation. Proc. Natl. Acad. Sci. U.S.A. 91, 8368– 8372 8078889 PMC44607
  105. Schwarzman A. L. Tsiper M. Wente H. Wang A. Vitek M. P. Vasiliev V. Goldgaber D. (2004). Amyloidogenic and anti-amyloidogenic properties of recombinant transthyretin variants. Amyloid 11, 1– 9 15185492
  106. Selenica M. L. Wang X. Ostergaard-Pedersen L. Westlind-Danielsson A. Grubb A. (2007). Cystatin C reduces the in vitro formation of soluble Aβ 1-oligomers and protofibrils. Scand. J. Clin. Lab. Invest. 67, 179– 190 10.1080/00365510601009738 17365997 · DOI
  107. Simonsen A. H. McGuire J. Podust V. N. Hagnelius N. O. Nilsson T. K. Kapaki E. Vassilopoulos D. Waldemar G. (2007). A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement. Geriatr. Cogn. Disord. 24, 434– 440 10.1159/000110576 17971664 · DOI
  108. Skerget K. Taler-Vercic A. Bavdek A. Hodnik V. Ceru S. Tusek-Znidaric M. Kumm T. Pitsi D. Pompe-Novak M. Palumaa P. Soriano S. Kopitar-Jerala N. Turk V. Anderluh G. Zerovnik E. (2010). Interaction between oligomers of stefin B and amyloid-β in vitro and in cells. J. Biol. Chem. 285, 3201– 3210 10.1074/jbc.M109.024620 19955183 PMC2823404 · DOI
  109. Steinhoff T. Moritz E. Wollmer M. A. Mohajeri M. H. Kins S. Nitsch R. M. (2001). Increased cystatin C in astrocytes of transgenic mice expressing the K670N-M671L mutation of the amyloid precursor protein and deposition in brain amyloid plaques. Neurobiol. Dis. 8, 647– 654 10.1006/nbdi.2001.0412 11493029 · DOI
  110. Sun Q. (1989). Growth stimulation of 3T3 fibroblasts by cystatin. Exp. Cell Res. 180, 150– 160 10.1016/0014-4827(89)90219-X 2783311 · DOI
  111. Sundelof J. Arnlov J. Ingelsson E. Sundstrom J. Basu S. Zethelius B. Larsson A. Irizarry M. C. Giedraitis V. Ronnemaa E. Degerman-Gunnarsson M. Hyman B. T. Basun H. Kilander L. Lannfelt L. (2008). Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology 71, 1072– 1079 10.1212/01.wnl.0000326894.40353.93 18824671 PMC2676985 · DOI
  112. Sundelof J. Sundstrom J. Hansson O. Eriksdotter-Jonhagen M. Giedraitis V. Larsson A. Degerman-Gunnarsson M. Ingelsson M. Minthon L. Blennow K. Kilander L. Basun H. Lannfelt L. (2010). Cystatin C levels are positively correlated with both Aβ 42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. J. Alzheimers Dis. 21, 471– 478 10.3233/JAD-2010-091594 20555147 · DOI · Paper page
  113. Taupin P. Ray J. Fischer W. H. Suhr S. T. Hakansson K. Grubb A. Gage F. H. (2000). FGF-2-Responsive neural stem cell proliferation requires CCg, a novel Autocrine/Paracrine cofactor. Neuron 28, 385– 397 10.1016/S0896-6273(00)00119-7 11144350 · DOI
  114. Tavera C. Leung-Tack J. Prevot D. Gensac M. C. Martinez J. Fulcrand P. Colle A. (1992). Cystatin C secretion by rat glomerular mesangial cells: autocrine loop for in vitro growth-promoting activity. Biochem. Biophys. Res. Commun. 182, 1082– 1088 10.1016/0006-291X(92)91842-E 1540157 · DOI
  115. Tizon B. Levy E. (2006). Protease inhibitors and their involvement in neurological disorders, in Handbook of Neurochemistry and Molecular Neurobiology, ed Lajtha A. (New York, NY: Springer Publishers), 591– 624
  116. Tizon B. Ribe E. M. Mi W. Troy C. M. Levy E. (2010a). Cystatin C protects neuronal cells from amyloid β-induced toxicity. J. Alzheimers Dis. 19, 665– 894 10.3233/JAD-2010-1291 20157244 PMC2889175 · DOI
  117. Tizon B. Sahoo S. Yu H. Gauthier S. Kumar A. R. Mohan P. Figliola M. Pawlik M. Grubb A. Uchiyama Y. Bandyopadhyay S. Cuervo A. M. Nixon R. A. Levy E. (2010b). Induction of autophagy by cystatin C: a mechanism that protects murine primary cortical neurons and neuronal cell lines. PLoS ONE 5: e9819 10.1371/journal.pone.0009819 20352108 PMC2843718 · DOI
  118. Tsuchiya K. Kohda Y. Yoshida M. Zhao L. Ueno T. Yamashita J. Yoshioka T. Kominami E. Yamashima T. (1999). Postictal blockade of ischemic hippocampal neuronal death in primates using selective cathepsin inhibitors. Exp. Neurol. 155, 187– 194 10.1006/exnr.1998.6988 10072294 · DOI
  119. Tsuji-Akimoto S. Yabe I. Niino M. Kikuchi S. Sasaki H. (2009). Cystatin C in cerebrospinal fluid as a biomarker of ALS. Neurosci. Lett. 452, 52– 55 19444952
  120. Tu G. F. Aldred A. R. Southwell B. R. Schreiber G. (1992). Strong conservation of the expression of cystatin C gene in choroid plexus. Am. J. Physiol. 263, R195– R200 1636787
  121. Turk B. Turk D. Turk V. (2000). Lysosomal cysteine proteases: more than scavengers. Biochim. Biophys. Acta 1477, 98– 111 10.1016/S0167-4838(99)00263-0 10708852 · DOI
  122. Turk V. Stoka V. Turk D. (2008). Cystatins: biochemical and structural properties, and medical relevance. Front. Biosci. 13, 5406– 5420 18508595
  123. Vinters H. V. (2001). Cerebral amyloid angiopathy: a microvascular link between parenchymal and vascular dementia? Ann. Neurol. 49, 691– 693 11409417
  124. Vinters H. V. Nishimura G. S. Secor D. L. Pardridge W. M. (1990). Immunoreactive A4 and γ-trace peptide colocalization in amyloidotic arteriolar lesions in brains of patients with Alzheimer's disease. Am. J. Pathol. 137, 233– 240 2201197 PMC1877627
  125. Walsh D. M. Selkoe D. J. (2004). Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 44, 181– 193 10.1016/j.neuron.2004.09.010 15450169 · DOI · Paper page
  126. Wang B. Xie Y. C. Yang Z. Peng D. Wang J. Zhou S. Li S. Ma X. (2008). Lack of an association between Alzheimer's disease and the cystatin C (CST3) gene G73A polymorphism in Mainland Chinese. Dement. Geriatr. Cogn. Disord. 25, 461– 464 10.1159/000125670 18408364 · DOI
  127. Wei L. Berman Y. Castano E. M. Cadene M. Beavis R. C. Devi L. Levy E. (1998). Instability of the amyloidogenic cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. J. Biol. Chem. 273, 11806– 11814 10.1074/jbc.273.19.11806 9565605 · DOI
  128. Wei L. Walker L. C. Levy E. (1996). Cystatin C: Icelandic-like mutation in an animal model of cerebrovascular β amyloidosis. Stroke 27, 2080– 2085 10.1161/01.STR.27.11.2080 8898820 · DOI
  129. Wilhelmus M. M. Boelens W. C. Otte-Holler I. Kamps B. de Waal R. M. Verbeek M. M. (2006). Small heat shock proteins inhibit amyloid-β protein aggregation and cerebrovascular amyloid-β protein toxicity. Brain Res. 1089, 67– 78 10.1016/j.brainres.2006.03.058 16635482 · DOI
  130. Wilhelmus M. M. de Waal R. M. Verbeek M. M. (2007). Heat shock proteins and amateur chaperones in amyloid-β accumulation and clearance in Alzheimer's disease. Mol. Neurobiol. 35, 203– 216 17917109 PMC2039847
  131. Wilson M. E. Boumaza I. Lacomis D. Bowser R. (2010). Cystatin C: a candidate biomarker for amyotrophic lateral sclerosis. PLoS ONE 5: e15133 10.1371/journal.pone.0015133 21151566 PMC3000338 · DOI
  132. Winkler D. T. Bondolfi L. Herzig M. C. Jann L. Calhoun M. E. Wiederhold K. H. Tolnay M. Staufenbiel M. Jucker M. (2001). Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J. Neurosci. 21, 1619– 1627 11222652 PMC6762950
  133. Wisniewski H. M. Terry R. D. (1973). Morphology of the aging brain, human and animal. Prog. Brain Res. 40, 167– 186 10.1016/S0079-6123(08)60686-X 4371053 · DOI
  134. Yamamoto-Watanabe Y. Watanabe M. Jackson M. Akimoto H. Sugimoto K. Yasujima M. Wakasaya Y. Matsubara E. Kawarabayashi T. Harigaya Y. Lyndon A. R. Shoji M. (2010). Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3. Brain Res. 1361, 140– 145 10.1016/j.brainres.2010.09.033 20849835 · DOI
  135. Yamashima T. Kohda Y. Tsuchiya K. Ueno T. Yamashita J. Yoshioka T. Kominami E. (1998). Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074, a novel strategy for neuroprotection based on ‘calpain-cathepsin hypothesis’. Eur. J. Neurosci. 10, 1723– 1733 10.1046/j.1460-9568.1998.00184.x 9751144 · DOI
  136. Yang H. T. Wilkening S. Iadarola M. J. (2001). Spinal cord genes enriched in rat dorsal horn and induced by noxious stimulation identified by subtraction cloning and differential hybridization. Neuroscience 103, 493– 502 10.1016/S0306-4522(00)00573-X 11246163 · DOI
  137. Yang Y. Liu S. Qin Z. Cui Y. Qin Y. Bai S. (2009). Alteration of cystatin C levels in cerebrospinal fluid of patients with Guillain-Barre syndrome by a proteomical approach. Mol. Biol. Rep. 36, 677– 682 10.1007/s11033-008-9228-1 18373213 · DOI
  138. Yasuhara O. Hanai K. Ohkubo I. Sasaki M. McGeer P. L. Kimura H. (1993). Expression of cystatin C in rat, monkey and human brains. Brain Res. 628, 85– 92 10.1016/0006-8993(93)90941-F 8313175 · DOI
  139. Ying G. X. Huang C. Jiang Z. H. Liu X. Jing N. H. Zhou C. F. (2002). Up-regulation of cystatin C expression in the murine hippocampus following perforant path transections. Neuroscience 112, 289– 298 10.1016/S0306-4522(02)00083-0 12044447 · DOI
  140. Zellner M. Veitinger M. Umlauf E. (2009). The role of proteomics in dementia and Alzheimer's disease. Acta Neuropathol. 118, 181– 195 10.1007/s00401-009-0502-7 19259691 · DOI
  141. Zerovnik E. Staniforth R. A. Turk D. (2010). Amyloid fibril formation by human stefins: structure, mechanism and putative functions. Biochimie 92, 1597– 1607 10.1016/j.biochi.2010.05.012 20685229 · DOI

Cited by

Sorted by citations

Metadata

Authors
Kaur, G., & Levy, E.
Venue
Frontiers in Molecular Neuroscience
Publisher
Frontiers Media SA
Published
2012
Volume
5
ISSN
1662-5099
DOI
10.3389/fnmol.2012.00079
PMC
PMC3390601
Cited by
116
References
7

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review